Related Experiment Videos
Metabolic effects of carvedilol in hypertensive patients
1Department of Geriatrics, Uppsala University, Sweden.
Insights
Carvedilol effectively lowers blood pressure in hypertensive patients. However, it may negatively impact glucose metabolism and lipid profiles, with potential benefits from its alpha-1 blocking properties.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Medicine
Background:
- Essential hypertension is a widespread cardiovascular condition.
- Carvedilol is a non-selective beta-blocker with alpha-1 blocking properties used for hypertension.
Purpose of the Study:
- To investigate the metabolic effects of carvedilol in patients with essential hypertension.
- To assess changes in lipid concentrations and insulin sensitivity.
Main Methods:
- A 4-6 week placebo-controlled period followed by a 6-month open-label carvedilol treatment.
- Metabolic investigations included hyperinsulinemic clamp tests and intravenous glucose tolerance tests.
- Dosage adjustments were permitted from 25 mg to 50 mg daily.
Main Results:
- Carvedilol significantly lowered blood pressure.
- Triglycerides increased by 13%, while HDL cholesterol decreased by 11%.
- Insulin sensitivity decreased by 17%, with increased insulin and glucose areas under the curve.
Conclusions:
- Carvedilol's alpha-1 blocking properties may moderate its effects on lipoproteins and insulin sensitivity compared to pure beta-blockers.
- The drug demonstrates efficacy in blood pressure reduction but warrants monitoring for metabolic side effects.
Objective:
Fifty-six patients with essential hypertension were recruited to study the metabolic effects of carvedilol, a non-selective beta-adrenoceptor-blocker with alpha 1-adrenoceptor blocking properties.
Methods:
The study started with a single-blind, 4-6-week placebo-treatment period followed by an open 6-month active treatment period. There was an option to increase the dose from 25 mg carvedilol to 50 mg daily after 6 weeks. Metabolic investigations were carried out at the end of the placebo period and at the end of the active treatment period.
Results:
The results show that during carvedilol treatment blood pressure was efficiently lowered. The increase in very low density lipoprotein triglyceride concentration was 13%. Despite this modest increase high density lipoprotein cholesterol was reduced by 11%. The metabolic clearance rate of glucose at the hyper-insulinemic clamp test (adjusted for the prevailing insulin and glucose concentrations) decreased by 17%. At the i.v. glucose tolerance test the insulin area under the curve was increased by 18% and the glucose area by 10%.
Conclusion:
The alpha 1-adrenoceptor-blocking characteristics of carvedilol probably explain the moderate changes of lipoprotein concentrations and insulin sensitivity gained compared with what is usually obtained with a non-selective beta-adrenoceptor-blocker.